Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.53 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.53 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.53 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | INSR | P06213 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | LYN | P07948 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | MET | P08581 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998769 | 0.90 | KIT (0.53) | KITCYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL1992563 | 0.88 | NTRK1 (0.58) | KITCYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL1993309 | 0.86 | KIT (0.47) | KITCYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL12615878 | 0.84 | KIT (0.64) | KITCYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL1997645 | 0.82 | EIF2AK4 (0.45) | KITFLT3JAK2IRAK1IRAK4 | |
| SCHEMBL1996723 | 0.81 | JAK2 (0.47) | KITCYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL1997445 | 0.80 | EIF2AK4 (0.43) | KITFLT3JAK2ABCG2IRAK1 | |
| SCHEMBL1995030 | 0.80 | EIF2AK4 (0.43) | KITFLT3JAK2ABCG2IRAK1 | |
| SCHEMBL1993894 | 0.79 | IRAK4 (0.46) | KITFLT3JAK2IRAK1IRAK4 | |
| SCHEMBL1999082 | 0.78 | NTRK1 (0.55) | KITCYP1A2CYP3A4CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | claimed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | claimed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | claimed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | claimed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | KIT 161/4885CYP1A2 877/4885CYP3A4 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.